tickrz reports
  
tickrz rank
D
Boston Scientific Corp (BSX)
Healthcare | Medical Appliances & Equipment
CEO: Michael F. Mahoney
Employees: 25000
bostonscientific.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank444Dividend RankNO DIVIDEND
Moat Rank417Financial Strength Rank299
Growth Rank391Momentum Rank206
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio87.31x
P/B Ratio5.39x
P/S Ratio4.43x
EV/EBITDA Ratio32.78x
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity78%
Interest Coverage2.1x
MOAT
ROE6.44%
ROIC7.33%
Net Margin4.14%
GROWTH
5 yr EPS Growth-2.92%
5 yr SPS Growth1.93%
5 yr BPS Growth-8.8%
tickrz Report
 tickrz summary
Boston Scientific Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Boston Scientific Corp's valuation score is comprised of a P/E ratio of 87.3x, a P/B ratio of 5.4x, a P/S ratio of 4.4x, and an EV/EBITDA ratio of 32.8x. Boston Scientific Corp ranks 444 out of the S&P 500 constituents on valuation--a relatively weak score.Boston Scientific Corp ranks 406 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Boston Scientific Corp is probably not for you.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Boston Scientific Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 2.1x, a debt/equity ratio of 78% and a Moat Rank of 417 translate to an average Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 15.12% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 206. Based on its 12 month stock performance, Boston Scientific Corp will not appeal to momentum investors.

 yield
 value + yield
Boston Scientific Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -2.9% 5 year annualized EPS growth, 1.9% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -8.8% speak to its relatively poor ranking.

Boston Scientific Corp (BSX)
Healthcare | Medical Appliances & Equipment
CEO: Michael F. Mahoney
Employees: 25000
bostonscientific.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio87.31x
P/B Ratio5.39x
P/S Ratio4.43x
EV/EBITDA Ratio32.78x
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity78%
Interest Coverage2.1x
MOAT
ROE6.44%
ROIC7.33%
Net Margin4.14%
GROWTH
5 yr EPS Growth-2.92%
5 yr SPS Growth1.93%
5 yr BPS Growth-8.8%

TICKRZ RANK
Boston Scientific Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Boston Scientific Corp's valuation score is comprised of a P/E ratio of 87.3x, a P/B ratio of 5.4x, a P/S ratio of 4.4x, and an EV/EBITDA ratio of 32.8x. Boston Scientific Corp ranks 444 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Boston Scientific Corp ranks 406 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Boston Scientific Corp is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Boston Scientific Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 2.1x, a debt/equity ratio of 78% and a Moat Rank of 417 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 15.12% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 206. Based on its 12 month stock performance, Boston Scientific Corp will not appeal to momentum investors.

VALUE + YIELD
Boston Scientific Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -2.9% 5 year annualized EPS growth, 1.9% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -8.8% speak to its relatively poor ranking.